The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Disparities Observed in Diabetic Retinopathy Rates By Gender, Ethnicity
Data show Black individuals had a 1.41 times higher odds of having type 2 diabetic retinopathy when compared to white individuals.
A Preview of the Ziltevekimab ZEUS Clinical Trial
Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.
EHR Alerts Improve Guideline-Directed Heart Failure Treatment Strategies
Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.
Omecamtiv Mecarbil Declines To Improve Exercise Capacity in Patients with HFrEF
Data show omecamtiv mecarbil added to background therapy had no significant improvement regarding exercise capacity.
Arrhythmia Monitoring May Remain Beneficial Despite Missing Primary Endpoints
Peter Sogaard discusses the benefit of monitoring for arrhythmias in patients with non-STEMI heart attacks and the need to look at arrhythmias in a different light.
CANTOS Data Show Importance of Inflammation Risk in CKD Patients with Atherosclerosis
Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.
Javed Butler, MD: Consistent Benefits of Finerenone On CV, Kidney Outcomes
Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D.
How Findings from SuperWIN May Shape the Future of Dietary Education
A discussion into broadening the findings of the SuperWIN trial and its potential effects on a larger, more at-risk population.
SuperWIN Nutrition Education in Grocery Stores Linked To Improved Dietary Quality
Dylan Steen, MD discusses positive findings from the trial on links between personalized education and DASH diet adherence.
What's Next for Lipoprotein(a) Lowering Agent SLN360
Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.
Sequential Smartwatch Readings for Atrial Fibrillation Have High Detection Rates
Once a day readings over a year would detect 98.3% of the first Afib >24 hour episodes, while the probability of ≥1 false positive reading would be 98%.
Evidence Builds for Bentracimab Reversing Antiplatelet Effect of Ticagrelor
Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.
Rivaroxaban Benefits LER Patients Safely Regardless of Chronic Kidney Disease
VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.
Investigator Perspectives on SODIUM-HF Outcomes, Dietary Changes For HF Care
Lead SODIUM-HF investigator Justin Ezekowitz provides insight into the trial and why dietary interventions may still be important for heart failure care.
Vupanorsen Falls Short Despite HDL-C Reduction in TRANSLATE-TIMI 70
Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.
PROMPT-HF, SODIUM-HF, and Improving Data-to-Practice Heart Failure Care
Larry Allen, MD, discusses some of ACC 2022's biggest contributions toward improving evidence-based care to patients with HF.
Javed Butler, MD: Clinical Benefits of Patiromer in Reducing Hyperkalemia
The majority of patients with HFrEF and RAASi-related hyperkalemia achieved optimal doses of RAASi when treated with patiromer.
Influenza Vaccine Shows No Significant Reduction in Major Cardiovascular Event Rate
No difference in the primary outcome was observed between those randomized to influenza vaccine compared to placebo.
Mavacamten May Be a Game Changing Treatment for Hypertrophic Cardiomyopathy
In a new interview from ACC 2022, Florian Rader, MD discusses the potential of the new medication for HCM and the need to monitor safety signals over the long-term.
Short-Interfering RNA Infusion SLN360 Lowers Lp(a) in Cardiovascular-Risk Patients
New phase 1 APOLLO data show the investigative single-dose siRNA infusion may address an inherent risk factor for severe cardiovascular events.
The Immediate Impact of the 2022 Heart Failure Guidelines
Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.
Obesity May Be Most Overlooked Component of ASCVD Prevention Among US Adults
A national survey assessment compared against the 6-item "ABCDs of ASCVD prevention" show the significant prevalence of obesity.
Milind Desai, MD: Next Steps for Mavacamten for Hypertrophic Cardiomyopathy
Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.
Bentracimab Reverses Antiplatelet Bleeding Effect of Ticagrelor in Phase 2b Trial
Investigators believe the novel monoclonal antibody may be a suitable agent in patients with major bleeding risk or those undergoing surgery.
Dietary Sodium Reduction Fails to Reduce Clinical Heart Failure Events
Findings from SODIUM-HF suggest strategies to reduce dietary sodium intake to less than 1500 mg daily were not more effective than usual care in reducing hospitalization risk.
Mavacamten Reduces Eligibility for SRT in Obstructive Hypertrophic Cardiomyopathy
Findings from VALOR-HCM suggest more data is needed to assess the durability of improvement in septal reduction therapy eligibility over longer time periods.
Treating Mild Chronic Hypertension in Pregnancy May Reduce Risk of Neonatal, Fetal Outcomes
New late-breaking ACC 2022 data support the use of antihypertensive therapy to reduce risk of events including preeclampsia and neonatal death among at-risk expecting mothers.
Lack of Interaction Observed For Treatment Effect of Empagliflozin By Region, Race
New research suggests a consistent risk reduction of empagliflozin may be theorized independent of region or race categories.
Valvular Heart Disease Increasingly Prevalent in Older Americans
An investigator discusses new ACC 2022 data showing valvular heart disease is disparately impacting older patients, as well as females, with previously unanticipated manifestations.
Omecamtiv Mecarbil Reduces Risk of CV Death in Hospitalized Patients with HFrEF
Hospitalized HFrEF patients had a higher rate of the cardiovascular death or a worsening heart failure event than outpatients